TURNING POINT THERAPEUTICS, INC.

(TPTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bristol Myers boosts cancer drug portfolio with $4.1 bln Turning Point deal

06/03/2022 | 07:13am EDT
FILE PHOTO: A woman holds test tube in front of displayed Bristol Myers Squibb logo in this illustration

June 3 (Reuters) - Bristol Myers Squibb Co said on Friday it will acquire drug developer Turning Point Therapeutics Inc for $4.1 billion in cash to help bolster its arsenal of cancer drugs.

Turning Point's lead drug, repotrectinib, targets mutations in certain proteins in the body that lead to unchecked cell growth.

Bristol Myers will pay $76 per Turning Point share, a 122.5% premium to its last closing price.

The deal comes at a time when a dearth of large acquisitions, clinical failures and investor exits following a gradual easing of the pandemic have hammered biotech stocks.

Wall Street analysts said the deal could help lift sector sentiment.

The deal "will surprise many investors who over the past year have begun to believe late-to-market targeted oncology drugs are likely to be commercial failures," Stifel analyst Bradley Canino said.

Turning Point's shares, which have fallen roughly 28% this year, more than doubled to $73.60 in early trading.

Repotrectinib belongs to a class of treatments known as tyrosine kinase inhibitors, and is being tested to treat non-small cell lung cancer (NSCLC) and other advanced solid tumors.

However, the drug, if approved, will compete in a crowded market for lung cancer treatments and contend for market share with Bristol Myers' own drug Opdivo, and other cancer drugs made by Roche, Merck & Co Inc and AstraZeneca .

Bristol Myers said it expects repotrectinib to become a standard-of-care therapy for certain patients with NSCLC, a lucrative market for drug developers, when it is approved.

Sales of Bristol Myers' Opdivo have fallen below those of rival Merck's blockbuster treatment, Keytruda.

Bristol Myers expects U.S. approval for repotrectinib in the second half of 2023.

(Reporting by Manas Mishra and Amruta Khandekar in Bengaluru; Editing by Maju Samuel and Shounak Dasgupta)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.05% 10968 Delayed Quote.26.32%
ROCHE HOLDING AG -0.71% 315.65 Delayed Quote.-16.14%
TURNING POINT THERAPEUTICS, INC. 0.66% 75.99 Delayed Quote.58.26%
All news about TURNING POINT THERAPEUTICS, INC.
07:59aBristol Myers, Turning Point Say Regulatory Waiting Period for Acquisition Expires; Dea..
MT
08/12Biotech stocks pin bounce back hopes on M&A boost
RE
08/08TURNING POINT THERAPEUTICS : Positive feedback from pre-new drug application (NDA) meeting..
PU
08/08TURNING POINT THERAPEUTICS : Q2 Earnings Snapshot
AQ
08/08TURNING POINT THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Con..
AQ
08/08Turning Point Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Si..
CI
08/08Turning Point Therapeutics Reports Second-Quarter 2022 Financial Results, Provides Oper..
AQ
08/08Turning Point Therapeutics, Inc. Provides Operational and Clinical Update
CI
07/27Turning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatme..
AQ
07/19Bristol Myers Squibb Extends Turning Point Tender Offer
MT
More news
Analyst Recommendations on TURNING POINT THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 10,5 M - -
Net income 2022 -392 M - -
Net cash 2022 710 M - -
P/E ratio 2022 -9,56x
Yield 2022 -
Capitalization 3 780 M 3 780 M -
EV / Sales 2022 292x
EV / Sales 2023 81,8x
Nbr of Employees 267
Free-Float 99,3%
Chart TURNING POINT THERAPEUTICS, INC.
Duration : Period :
Turning Point Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TURNING POINT THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Last Close Price 75,49 $
Average target price 76,00 $
Spread / Average Target 0,68%
EPS Revisions
Managers and Directors
Athena M. Countouriotis President, Chief Executive Officer & Director
Paolo Tombesi Executive VP, Chief Financial & Accounting Officer
Mark J. Alles Chairman
Mohammad Hirmand Chief Medical Officer & Executive Vice President
Ed Gemo Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
TURNING POINT THERAPEUTICS, INC.58.26%3 780
GILEAD SCIENCES, INC.-8.81%82 985
VERTEX PHARMACEUTICALS39.13%78 356
REGENERON PHARMACEUTICALS, INC.1.86%68 773
WUXI APPTEC CO., LTD.-20.33%40 492
BIONTECH SE-36.97%39 486